ABSTRACT
Clinical data and courses of the disease of 56 patients with non-Hodgkin-lymphomas of high malignancy were demonstrated. The age-depending summit of the frequency was between the 51st and 60th year of age, the age median was about 48 years. The initial remission rate three months after the beginning of the therapy was 66%. Out of the responders in 44% relapsed, in which cases 70% of the relapses developed in the first year after the beginning of treatment. After twelve months the survival rate was 0.52 and after 48 months 0.32. Patients with initial remission, with localized stages I and II (Ann Arbor) as well as with primarily extranodal manifestation and with histology of centroblastoma had a clear prognostic advantage. Initial B-symptomas, an advanced stage of the disease and a histology of immunoblastoma and lymphoblastoma as well were negatively correlated to the prognosis.
Subject(s)
Lymphoma, Non-Hodgkin/diagnosis , Adolescent , Adult , Aged , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Combined Modality Therapy , Female , Humans , Lymphoma, Non-Hodgkin/pathology , Lymphoma, Non-Hodgkin/therapy , Male , Middle Aged , Neoplasm Staging , PrognosisABSTRACT
A case of 75 year-old man is reported, who died of a tuberculous leptomeningomyeloencephalitis complicating a generalized primary lymph node plasmacytoma. The malignant lymphoma has been diagnosed in a lymph node biopsy from the right supraclavicular region seven years before the death and was treated with cytostatics over a period of four and a half months. Autopsy revealed the neoplastic involvement of supraclavicular and axillary lymph nodes, tumour infiltration of the sternum and diffuse neoplastic plasmacytosis of the bone marrow. The lymph node plasmacytoma has to be differentiated from reactive lymph node plasmacytosis, angioimmunoblastic lymphadenopathy with excessive plasmacytosis, lymphoplasmacytic immunocytoma, metastasis of an extramedullary plasmacytoma or of a multiple myeloma, and from a lymph node involved by plasma-cell leukemia.
Subject(s)
Plasmacytoma/diagnosis , Aged , Biopsy , Diagnosis, Differential , Humans , Lymph Nodes/pathology , Lymphoma/diagnosis , Male , Multiple Myeloma/diagnosis , Neoplasm Invasiveness , Neoplasm Metastasis , Plasmacytoma/complications , Plasmacytoma/pathology , Tuberculosis, Meningeal/complicationsABSTRACT
Of 146 patients with lymphogranulomatosis biochemical parameters were tested for their diagnostic valency concerning the recognition of a liver infiltration. In patients with histologically proved affection of the liver the AP, GGTP, AAP, LAP and LDH show a significant increase in comparison to the enzyme values of the patients without any hepatic manifestation. In an increased result of 4 enzyme values with a probability of 85% muste be reckoned with a participation of the liver. The enzyme SGOT, SGPT, GDH, LDH-isoenzymes, choline esterase, beta-GC, the De Ritis quotient and the quotient (Formula: see text), on the other hand, do not give any additional differential-diagnostic information.
Subject(s)
Hodgkin Disease/complications , Liver/enzymology , Acid Phosphatase/metabolism , Alanine Transaminase/metabolism , Aspartate Aminotransferases/metabolism , Cholinesterases/metabolism , Female , Glucuronidase/metabolism , Glutamate Dehydrogenase/metabolism , Humans , Isoenzymes , L-Lactate Dehydrogenase/metabolism , Liver Diseases/etiology , MaleABSTRACT
In haematological systemic diseases such as acute and chronic leukoses, malignant lymphomas, lymphogranulomatoses, osteomyelofibroses, polycythaemias and aplastic anaemias with a different proportion changes of the bones in form of osteoporoses, osteolytic processes and deformations of the vertebral bodies are to be found. The proof may be performed radiologically and histologically. In 461 patients with different haematological diseases absorption measurings of monoenergetic rays of a J-125-source were performed at the distal third of radius and ulna. It was shown that the bone mineral content of patients with proved bone destructions did not significantly differ from the normal group. The too peripherally located place of the measuring and also the late inclusion of the compacta into the changes is regarded as cause for the negative result.
Subject(s)
Bone Diseases/etiology , Leukemia/complications , Lymphoma/complications , Humans , Osteolysis/etiology , Osteoporosis/etiology , Spinal Diseases/etiologyABSTRACT
In 84 patients with chronic myeloid leukaemia receiving a cytostatic monotherapy with busulfan, an aplastic syndrome developed which was confirmed by a biopsy of the pelvis crest and examination of the sternal marrow. The time interval until pancytopenia was detected varied considerably in each case, ranging between 6 and 126 months. There are no correlations to the initial doses of busulfan. 3 patients died of the immediate effects of the bone-marrow damage caused by busulfan. In 4 from 6 of the following pancytopenic patients the leukocyte values lay between 12,800/microliter and 80,400 microliter when busulfan adminstration was interrupted. Thus, it is scarcely possible to give any reliable informations about a leukocyte limit value as a standard for an interruption of therapy in order to prevent bone-marrow aplasia. Taking this into account, the conclusion may be drawn that relatively short control intervals have to be made in this monochemotherapy of CML which often can be used successfully for many years.